

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Submission for OMB Review; Comment Request**

*Title:* Trafficking Victims Tracking System.

*OMB No.:* 0970—NEW.

*Description:* The Trafficking Victims Protection Act, Public Law 106–386, Division A, 114 Stat. 1464 (2000), requires the Department of Health and Human Services (HHS) to certify adult alien (“foreign”) victims of severe forms of trafficking in persons (“human trafficking”) who are willing to assist law enforcement in the investigation and prosecution of human trafficking, unless unable to cooperate due to physical or psychological trauma, and who have either made a bona fide application for T nonimmigrant status that has not been denied or been granted Continued Presence (CP) from the U.S. Department of Homeland Security (DHS). Issued by the Office of Refugee Resettlement (ORR) within the HHS Administration for Children and Families, certification letters grant adult foreign victims of human trafficking access to federal and state benefits and services to the same extent as refugees.

In general, ORR initiates the certification process when it receives a

notice from DHS that DHS has granted a foreign victim of trafficking CP or T nonimmigrant status, or has determined an application for T nonimmigrant status is bona fide. To issue certification letters, it is necessary for ORR to collect information from a victim’s representative, such as an attorney, case manager, or law enforcement victim specialist, including an address to send the letter. In line with other ORR Anti-Trafficking in Persons Program activities, ORR may ask if the victim is in need of a service provider and the current location (city, state) of the victim, and refer the victim to an appropriate service provider in his or her area, if requested. ORR will also ask about the victim’s language and urgent concerns, such as medical care or housing, and transmit this information to the service provider.

Finally ORR collects information, such as the victim’s sex and the type of human trafficking the victim experienced, to provide to Congress in an annual report on U.S. Government activities to combat trafficking that is prepared by the U.S. Department of Justice. Congress requires HHS and other appropriate Federal agencies to report, at a minimum, information on the number of persons who received benefits or other services under subsections (b) and (f) of section 7105 of Title 22 of the U.S. Code, the TVPA, in connection with programs or activities

funded or administered by HHS. HHS includes in these annual reports additional information about the victims that it collects when assisting each victim to obtain certification or eligibility. ORR will store this information and any other details regarding the victim’s case in the Trafficking Victims Tracking System (TVTS) on ORR’s secure database. Other details maintained in the victim’s file may include ORR staff actions, referrals, and notes regarding the victim’s interest in receiving services. Maintaining victim records on TVTS will ensure efficient service for victims, allow ORR staff to track victims’ progress toward certification, verify their eligibility for benefits, and organize information for reporting to Congress.

The TVTS also includes information about foreign victims of trafficking and potential victims who were minors when an eligibility letter was sought from ORR. Information about these individuals is collected pursuant to an OMB-approved collection, OMB Control Number 0970–0362.

In January 2011, the Archivist of the United States approved an Electronic System Schedule for the disposition of TVTS records.

*Respondents:* Respondents can include attorneys, legal representatives, social service providers, case managers, and volunteers acting on behalf of the adult foreign victim of trafficking.

**ANNUAL BURDEN ESTIMATES**

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
	800	1	.1	80

*Estimated Total Annual Burden Hours:* 80.

*Additional Information:* Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L’Enfant Promenade SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov).

*OMB Comment:* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the

proposed information collection should be sent directly to the following:

Office of Management and Budget, Paperwork Reduction Project, Email: [OIRA\\_SUBMISSION@OMB.EOP.GOV](mailto:OIRA_SUBMISSION@OMB.EOP.GOV), Attn: Desk Officer for the Administration for Children and Families.

**Robert Sargis,**

*Reports Clearance Officer.*

[FR Doc. 2014–26723 Filed 11–10–14; 8:45 am]

**BILLING CODE 4184–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2014–N–1794]

**Agency Information Collection Activities; Proposed Collection; Comment Request; Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-to-Consumer Prescription Drug Ads**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain



To examine differences between experimental conditions, we will conduct inferential statistical tests such as analysis of variance. With the sample

size described in the following table, we will have sufficient power to detect small-to-medium sized effects in the main study.

FDA estimates the burden of this collection of information as follows:

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>

Activity	Number of respondents	Number of responses per respondent	Total annual respondents	Average burden per response	Total hours
Pretest 1 screener completes (assumes 10% eligible)	4,150	1	4,150	0.08 (5 minutes) .....	332
Pretest 2 screener completes (assumes 10% eligible)	4,150	1	4,150	0.08 (5 minutes) .....	332
Number of main study screener completes (assumes 10% eligible).	620	1	620	0.08 (5 minutes) .....	50
Pretest 1 completes .....	420	1	420	2 .....	840
Pretest 2 completes .....	420	1	420	2 .....	840
Number of completes, main study .....	620	1	620	2 .....	1240
<b>Total .....</b>					<b>3,634</b>

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

**References**

The following references have been placed on display in the Division of Dockets Management (see **ADDRESSES**) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday, and are available electronically at <http://www.regulations.gov>.

1. Singh, S. N., D. Linville, and A. Sukhdial, "Enhancing the Efficacy of Split Thirty-Second Television Commercials: An Encoding Variability Application," *Journal of Advertising*, 24, pp. 13–23 (1995).
2. Haugtvedt, C. P., et al., "Advertising Repetition and Variation Strategies: Implications for Understanding Attitude Strength," *Journal of Consumer Research*, 21, pp. 176–189 (1994).
3. Naples, M. J., "Effective Frequency: Then and Now," *Journal of Advertising Research*, 37, pp. 7–12 (1997).

Dated: November 5, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014–26698 Filed 11–10–14; 8:45 am]

**BILLING CODE 4164–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2013–F–1539]

**DSM Nutritional Products; Food Additive Petition (Animal Use); Ethoxyquin; Environmental Assessment**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of an environmental

assessment filed by DSM Nutritional Products in support of their petition proposing that the food additive regulations be amended to provide for the safe use of ethoxyquin in vitamin D formulations, including 25-hydroxyvitamin D<sub>3</sub>, used in animal food.

**ADDRESSES:** Submit electronic comments to: <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Isabel W. Pocurull, Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–453–6853.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of December 23, 2013 (78 FR 77384) FDA published notice that a food additive petition (FAP) had been filed by DSM Nutritional Products, 45 Waterview Blvd., Parsippany, NJ 07054. The petition (FAP 2276) proposes to amend Title 21 of the Code of Federal Regulations (CFR) in part 573 *Food Additives Permitted in Feed and Drinking Water of Animals* (21 CFR part 573) to provide for the safe use of ethoxyquin as a chemical preservative in vitamin D formulations, including 25-hydroxyvitamin D<sub>3</sub>, used in animal food. In that document, FDA noted that the petitioner had requested a categorical exclusion from preparing an environmental assessment or environmental impact statement under 21 CFR 25.32(k).

Upon further review and request by FDA, the petitioner has filed an environmental assessment. To encourage public participation consistent with regulations issued under

the National Environmental Policy Act (40 CFR 1501.4(b)), the Agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Division of Dockets Management (see **ADDRESSES**) for public review and comment.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) electronic or written comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the Agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the Agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.51(b).

Dated: November 6, 2014.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. 2014–26709 Filed 11–10–14; 8:45 am]

**BILLING CODE 4164–01–P**